Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant. (PubMed, Am J Hematol) - May 18, 2026 - "Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. In conclusion, the risk of CMV infection remains clinically significant until Day + 180, although this is affected by the GVHD status of the patient. Discontinuation of letermovir may be considered after Day + 180."
Journal • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation
|
|
Amanda Olson; Betul Oran; Elizabeth J Shpall; Ella J Ariza-Heredia; Fareed Khawaja; George L Chen; Katayoun Rezvani; May Daher; Partow Kebriaei; Portia Smallbone; Richard Champlin; Rohtesh S Mehta; Roland Bassett; Roy F Chemaly; Uday Popat; Yosra Aljawai
|